SOF-SKN™ passes required *in vitro* safety tests

Highlights

- ***In vitro* safety studies are regulatory requirement before clinical trials**
- **Four studies successfully completed**
- **Stringent studies meet international standards**

Sydney, 4 February 2025: Innovative biotech company **Noxopharm Limited (ASX:NOX)** is pleased to announce its SOF-SKN™ lupus medication has successfully passed a set of important preclinical safety tests ahead of the upcoming HERACLES clinical trial.

These tests are a requisite part of drug development prior to a Phase 1 clinical trial. Two of the tests were designed to show that SOF-SKN's active ingredient would not be likely to cause genetic mutations (*in vitro* micronucleus and AMES tests), while a third measured the potential for cardiac toxicity (hERG study).

SOF-SKN's active ingredient passed the two *in vitro* genotoxicity studies and the cardiac safety test with no safety issues identified.

These three studies were performed under international Good Laboratory Practice (GLP) standards, which assure a high level of quality and integrity of preclinical safety data. This stringency is required to satisfy regulatory authorities when applying for human trials.

A fourth study examined the safety of the drug when exposed to UV light (3T3 assay), which is especially relevant for a topical treatment. Again, SOF-SKN passed this test with no safety issues identified.

The company is also currently undertaking the final *in vivo* study required by regulations as part of the clinical trial preparations, and will update shareholders on this in due course.

Noxopharm CEO Dr Gisela Mautner said: "Successfully passing these safety tests takes us a significant step closer to the clinic. They give us confidence that SOF-SKN will be safe for use in the HERACLES trial, and we will continue our preparations as quickly and efficiently as possible."

-ENDS-

About Noxopharm

Noxopharm Limited (ASX:NOX) is an innovative Australian biotech company discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance mRNA vaccines.

The company utilises specialist in-house capabilities and strategic partnerships with leading researchers to build a growing pipeline of new proprietary drugs based on two technology platforms – Chroma™ (oncology) and Sofra™ (inflammation, autoimmunity, and mRNA vaccine enhancement).

Noxopharm also has a major shareholding in US registered, Australia based Nyrada Inc (ASX: NYR), a drug discovery and development company specialising in novel small molecule therapies.

To learn more, please visit: noxopharm.com

Investor, Corporate & Media enquiries:
Julian Elliott
M: 0425 840 071
E: julian.elliott@noxopharm.com

Company Secretary:
David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Dr Gisela Mautner, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control (including but not limited to the COVID-19 pandemic) that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.